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The SCHOLAR-1 international retrospective study highlighted poor clinical outcomes and
survivalamongpatientswithrefractory largeB-cell lymphoma(LBCL) treatedwithconventional
chemotherapy. Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen
receptor (CAR) T-cell therapy, demonstrated durable responses in patientswith refractory LBCL
in the pivotal phase 1/2 ZUMA-1 study (NCT02348216). Here, we compared SCHOLAR-1with the
2-year outcomes of ZUMA-1. Prior to comparison of clinical outcomes, propensity scoring (based
on a broad set of prognostic covariates) was used to create balance between ZUMA-1 and
SCHOLAR-1 patients. In the pivotal phase 2 portion of ZUMA-1, 101 patients received axi-cel and
were evaluable for response and survival. In SCHOLAR-1, 434 and 424 patients were evaluable
for response and survival, respectively. ZUMA-1 patients were more heavily pretreated than
were SCHOLAR-1 patients. The median follow-up was 27.1 months in ZUMA-1. The objective
responserate (ORR)andcompleteresponseratewere83%and54% inZUMA-1vs34%and12% in
SCHOLAR-1, respectively. The 2-year survival rate was 54% in ZUMA-1 and 20% in SCHOLAR-1,
and a 73% reduction in the risk of death was observed in ZUMA-1 vs SCHOLAR-1. These results
were consistentwith thoseofanadditional standardizationanalysis inwhichstratawere limited
to 2 prognostic factors (refractory categorization and presence/absence of stem cell transplant
after refractoriness to chemotherapy) to conserve sample size. Despite the limitations of a non-
randomized analysis, these results indicate that axi-cel produces durable responses and a sub-
stantial survival benefit vs non–CAR T-cell salvage regimens for patients with refractory LBCL.
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Advances First Edition 3 September 2021; final version published online 22 October
2021. DOI 10.1182/bloodadvances.2020003848.
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Survival rates in large B-cell lymphoma (LBCL), the most common
subtype of non-Hodgkin lymphoma, have improved over the past
few decades in the United States and Europe. 1-3 However, the prog-
nosis of patients with relapsed or refractory disease remains poor, and
potentially curative options are few.4,5 Of patients who progress dur-
ing initial immunochemotherapy or within 1 year after first remission,
only 30% to 40%will respond to salvage chemotherapy andmay sub-
sequently undergo consolidation with autologous stem cell transplant
(ASCT).6-8 Approximately 50% of patients with relapsed or refractory
LBCLwho respond to salvage therapy and are able to undergo ASCT
will ultimately relapse after transplant.9 The prognosis is particularly
poor among those who have high-risk factors, such as a secondary
International Prognostic Index (IPI) score .2 or relapse #12 months
post-ASCT.8 Thus, most patients with refractory LBCL have no cura-
tive treatment options.4,5,8
The poor outcomes, including low overall survival (OS) rates, for
patients with refractory LBCL were highlighted in the SCHOLAR-1
study, the largest published international retrospective analysis of out-
comes in this patient population.4 Refractory status was defined as
progressive disease as best response to any line of chemotherapy,
stable disease as best response to $4 cycles of first-line therapy or
$2 cycles of later-line therapy, or relapse ,12 months after ASCT.
Patient-level data were collected for patientswith refractory LBCL sub-
types, including diffuse LBCL, transformed follicular lymphoma, and
primary mediastinal B-cell lymphoma.4 Among these patients, the
objective response rate (ORR) was 26%, the complete response
(CR) rate was 7%, and the median OS was 6.3 months with standard
salvage therapies.4 These findings underscored the considerable
unmet need for effective therapies for patients with refractory LBCL
and have served as benchmarks for assessing novel therapies in
this patient population. Chimeric antigen receptor (CAR) T-cell thera-
pies have emerged as an effective treatment approach for patients
with refractory aggressive lymphomas, and those targeting CD19
have shown high response rates in patients with refractory LBCL after
failure of conventional therapy.10-12 ZUMA-1 (NCT02348216) is the
pivotal multicenter single-arm phase 1/2 study evaluating axicabta-
gene ciloleucel (axi-cel), an autologous anti-CD19 CAR T-cell therapy,
in patients with refractory LBCL that supported the approval of axi-cel
in the United States and Europe.10,13,14 The ORR was 83%, the CR
rate was 58%, and themedianOSwas not reached (95% confidence
interval [CI], 12.8months-not estimable) after$2 years of follow-up for
all patients.13 In an updated analysis with a median follow-up of 39.1
months, the median OSwas 25.8 months and the 3-year OS rate was
47%.15 In the absence of a randomized trial, comparison with a histor-
ical control group consisting of patients with characteristics similar to
those in the ZUMA-1 trial is likely to be informative when assessing the
effectiveness of axi-cel over available non–CAR T-cell salvage thera-
pies, especially with longer follow-up. Here, we used propensity scor-
ing to adjust for imbalances in baseline characteristics prior to
comparison of 2-year clinical outcomes in SCHOLAR-1 and ZUMA-1.
Methods
Studies compared
The SCHOLAR-1 study design and cohort details were previously
described.4 Briefly, patient-level data were collected for patients
with refractory LBCL from 4 cohorts (N5636), including 2 observa-
tional institutional cohorts and 2 large phase 3, randomized controlled
trials: MD Anderson Cancer Center study,16 University of Iowa/Mayo
Clinic SPORE,17,18 Canadian Cancer Trials Group LY.12 phase 3
randomized study,6 and the Lymphoma Academic Research Organi-
zation CORAL randomized study.7-9 Patients must have received a
prior anti-CD20 antibody and an anthracycline-containing regimen.
For University of Iowa/Mayo Clinic SPORE, LY.12, and CORAL,
patients were included at the first instance of meeting refractory crite-
ria, whereas at the MD Anderson Cancer Center, patients who first
met refractory criteria from second-line therapy onward were included
(supplemental Table 1).4 The median follow-up from the overall
SCHOLAR-1 study ranged from 7.6 to 14.8 years across cohorts.4,13
For the purpose of comparing outcomes with ZUMA-1, salvage ther-
apy in SCHOLAR-1 was the next line of therapy after determination of
refractory status (see supplemental Methods for additional details).
ZUMA-1 is a single-armmulticenter phase 1/2 study of axi-cel in refrac-
tory LBCL, including diffuse LBCL, primary mediastinal B-cell lym-
phoma, and transformed follicular lymphoma, that is being
conducted at 22 medical cancer centers in the United States and
Israel.10,13,14 Patients had refractory disease and also must have
received a prior anti-CD20 antibody and an anthracycline-containing
regimen. Patients with central nervous system lymphoma at screening
or a history of central nervous system lymphoma were excluded. Fol-
lowing leukapheresis and the manufacture of CAR T cells, patients
received lymphodepleting chemotherapy with fludarabine (30 mg/m2
body surface area per day) and cyclophosphamide (500 mg/m2
body surface area per day) for 3 days, followed by axi-cel infusion at
a target dose of 23 106CART cells per kilogram.10,13 The data cutoff
date for this analysis was 11 August 2018, consistent with that of the
2-year long-term analysis of efficacy and safety outcomes (median
follow-up, 2.3 years).13 Asmentioned, the criteria for refractory disease
were consistent between SCHOLAR-1 and ZUMA-1. This study was
an analysis of published data and did not require Institutional Review
Board or Institutional Animal Care and Use Committee approval.
Assessments
For these analyses, responses in ZUMA-1 were determined based on
the revised International Working Group criteria for malignant lym-
phoma19 per investigator assessment.13 Assessments included
ORR, CR rate, and OS. In SCHOLAR-1, response to therapy was
determined based on InternationalWorkingGroup response criteria20
per investigator assessment for the 2 observational cohorts and per
local review of computerized tomography scans for the phase 3 trial
cohorts.4
Propensity scoring
Propensity scoring was used to create balance between the ZUMA-1
and SCHOLAR-1 patient cohorts21 andwas performed in accordance
with the previous propensity score–balanced comparison of 1-year
outcomes between ZUMA-1 and SCHOLAR-1 (Figure 1A).22 Propen-
sity scores were calculated for each patient by combining the ZUMA-1
and SCHOLAR patients into a single dataset and calculating the prob-
ability of being in the ZUMA-1 trial based on demographics and dis-
ease characteristics. The primary common support set for response
was based on the primary propensity model, which incorporated 7
covariates: age (at determination of refractory status), sex, disease
type (diffuse large B-cell lymphoma, transformed follicular lymphoma,
or primary mediastinal B-cell lymphoma), relapse within 12 months of
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ASCT, whether the patient was ever primary refractory (refractory to
the initial chemotherapy regardless of refractoriness to subsequent
lines of therapy) or refractory to$2 consecutive lines of chemotherapy,
and the number of prior lines of chemotherapy. An additional sensitivity
common support set for responsewas based on the sensitivity propen-
sity model, which incorporated age, sex, disease type, ever primary
refractory, refractory or not to $2 consecutive lines of chemotherapy,
number of prior lines of chemotherapy, IPI score, and disease stage
(when collected within 3 months of determination of refractory status).
Additionally, the presence of posttreatment stem cell transplant (SCT)
was added as a time-varying covariate in propensity models used to
determine the primary and sensitivity common support sets for survival
(supplemental Table 2). The statistician developing the common sup-
port data sets had access to the treatment status and covariate values
for each patient but did not reference outcomes.
Within the common support data sets, treatment differences in
response and survival for axi-cel vs the historical standard of care
(ie, non–CAR T-cell therapy) were evaluated. Estimators utilizing strat-
ification with regression adjustment were used to estimate the aver-
age treatment effect (ATE) of axi-cel for the ORR and CR end
points. ATE was the difference in the response rates that would be
expected if both groups of patients had been treated with axi-cel in
ZUMA-1 vs if both groups had received salvage chemotherapy in
SCHOLAR-1.23 Augmented inverse-probability weighted complete-
case estimators24 were used to adjust for the effects of confounding
covariates and censoring in the calculation of the survival functions.
The difference between these treatment-specific survival functions
were calculated: this difference function is the survival-function analog
of the ATE. From the treatment-specific survival functions, the
treatment-specific median OS times and their differences were calcu-
lated, along with treatment-specific OS rates at 3, 6, and 12 months.
Among patients in the primary common support set for survival, strat-
ification with regression-adjustment hazard ratio estimator was used
to estimate the hazard ratio between treatments. Bootstrap 95%
CIs were calculated for all quantities.
Standardization analysis
An additional standardized analysis was performed to minimize loss
of patients due to missing covariate data. Figure 1 compares the
derivation of analysis populations in the standardization analysis with
the aforementioned propensity score–balanced analysis. To address
potential imbalances in refractory status that could affect outcomes,
the standardization analyses25 equally weighted proportions of
patients by refractory categorization (ie, primary refractory, refractory
to $2 lines of therapy, or relapse within 1 year after SCT), as well
as the presence of ASCT or allogeneic SCT after establishing refrac-
toriness to chemotherapy (postrefractory SCT) in each study (supple-
mental Figure 1). The response rates, survival rates, or median OS
estimates from these strata within SCHOLAR-1 were weighted by
the proportion of patients in those strata within ZUMA-1 to calculate
an overall estimate that reflected the distribution across those strata
within ZUMA-1. Strata were limited to these 2 factors (ie, refractory
categorization and presence of postrefractory SCT), because an
increased number of prognostic factors would lead to a sparsity of
patients across additional strata. Statistical methods are described
in supplemental Methods.
Results
Demographics and baseline characteristics
Demographics and baseline characteristics for ZUMA-1 and
SCHOLAR-1 patients were published previously.4,10 The primary
and sensitivity common support sets were based on patient subset-
ting (supplemental Table 2) and then propensity scoring, as described
in supplemental Methods. Complete patient accountability is summa-
rized in supplemental Table 3.
Baseline characteristics for the primary common support sets for
response (ZUMA-1, N580; SCHOLAR-1, N5340) and
survival (ZUMA-1, N581; SCHOLAR-1, N5331) are presented in
Table 1. The sensitivity common support set for response and
survival included substantially fewer patients (ZUMA-1, N530;
SCHOLAR-1, N578); thus, the primary common support set was
our focus.
Among the primary common support sets for response and survival,
similar proportions were male in ZUMA-1 and SCHOLAR-1; more
patients were $65 years old in ZUMA-1 (Table 1). In general,



























Figure 1. Overview of analysis populations for propensity score–balanced and standardized comparisons. (A) Propensity scores were derived to generate a primary
and sensitivity common support data set for ZUMA-1 and SCHOLAR-1, which were then used to estimate the average treatment differences in response to and survival for anti-
CD19 CAR T-cell therapy and historical standard of care (non–CAR T-cell therapy). (B) Strata by refractory category and postrefractory SCT for standardization are depicted.
Standardized analyses were conducted that equally weighted the proportions of patients by refractory categorization and presence of autologous or allogeneic SCT after
establishing refractoriness to salvage therapy (postrefractory SCT) in each study.
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received $3 lines of therapy (chemotherapy or ASCT) in ZUMA-1. A
greater proportion of ZUMA-1 patients had stage III-IV disease and
high-intermediate or high-risk IPI classification (score $3). Compara-
tively, fewer ZUMA-1 patients received SCT any time after refractory
disease compared with SCHOLAR-1 patients. Demographics and
baseline characteristics for the standardization analysis are summa-
rized in supplemental Table 4.
Response rates
Among the primary common support set, the ORR and CR rates in
ZUMA-1 vs SCHOLAR-1 were 83% and 54% vs 34% and 12%,
respectively (Table 2). The respective ATEs of axi-cel for ORR and
CR were 49% (95% CI, 34-63%) and 42% (95% CI, 26-59%). In
the sensitivity common support set, ATEs were 36% (95% CI, 15-
61%) and 33% (95% CI, 3-51%) for ORR and CR, respectively. A
standardized comparison of ORR and CR rates also strongly favored
axi-cel (supplemental Table 5).
OS
Median follow-up in ZUMA-1 was 27.1 months. In the primary com-
mon support set, the median OS was 31.0 months (95% CI, 11.5
months-not estimable) in ZUMA-1 and 5.4 months (95% CI, 4.6-6.3
months) in SCHOLAR-1 (Figure 2). The treatment difference sug-
gested a 73% reduction in the risk of death in ZUMA-1 vs
SCHOLAR-1 (Table 3). In the sensitivity common support set, the
treatment difference suggested a 77% reduction in the risk of death
in ZUMA-1. The 2-year survival rate after propensity score analysis
was 54% (95% CI, 30-80%) in ZUMA-1 vs 20% (95% CI, 16-
26%) in SCHOLAR-1.
In the standardization analysis, the median OS was not reached in
ZUMA-1 (27.1 months of follow-up; 95%CI, 11.5 months-not estima-
ble) but was 4.1 months (95% CI, 3.5-5.1 months) in SCHOLAR-1
(supplemental Table 6). Similar to the findings in the primary and
sensitivity common support sets, standardized comparison resulted
in a 73% reduction in the risk of death in ZUMA-1 vs SCHOLAR-1
(supplemental Table 6). Two-year OS rates were 50% and 12%,
respectively (supplemental Figure 2; supplemental Table 6). Notably,
for patients who relapsed post-SCT and underwent postrefractory
SCT, the 2-year OS rate was greater in ZUMA-1 vs SCHOLAR-1
(50% vs 22%), although ZUMA-1 patient numbers were small
(supplemental Table 6). Similar 2-year OS rates were observed in
ZUMA-1 vs SCHOLAR-1 for patients who were refractory to$2 lines
of therapy and later underwent SCT (40% vs 42%). Complete OS
results from the standardization analysis are presented in supplemen-
tal Table 6.
Discussion
Evaluation of the benefit of a novel therapy in LBCL cannot rely solely on
response rates; it must also include long-term survival. CAR T-cell ther-
apy is considered a major breakthrough in the treatment of refractory
LBCL, but its approval and potential benefit vs risks, which includeman-
ageable toxicities, were based on single-arm phase 2 trials.10,11 These
Table 1. Baseline patient characteristics of primary common support sets for response and survival
Characteristics
Common support set for response Common support set for survival
ZUMA-1 (N 5 80) SCHOLAR-1 (N 5 340) ZUMA-1 (N 5 81) SCHOLAR-1 (N 5 331)
Male sex 53 (66) 231 (68) 54 (67) 225 (68)
Age $65 y 19 (24) 56 (16) 19 (23) 51 (15)
$3 lines of chemotherapy and ASCT* 49 (61) 98 (29) 50 (62) 93 (28)
Ever primary refractory† 23 (29) 126 (37) 23 (28) 125 (38)
Refractory to $2 consecutive lines of therapy 43 (54) 170 (50) 43 (53) 165 (50)
SCT any time after refractory disease 14 (18) 126 (37) 14 (17) 125 (38)
Relapse within 12 mo of ASCT 16 (20) 74 (22) 16 (20) 71 (21)
ECOG PS 0-1‡ 80 (100) 126/126 (100)§ 81 (100) 126/126 (100)§
Disease stage III-IV‡ 67 (84) 80/124 (65)§ 68 (84) 80/124 (65)§
IPI score $3‡ 34 (43) 33/119 (28)§ 35 (43) 33/119 (28)§
Unless otherwise noted, data are n (%).
ECOG PS, Eastern Cooperative Oncology Group Performance Status.
*Either prior to ZUMA-1 or prior to and including the qualifying line of therapy (ie, the next-to-last treatment a SCHOLAR-1 patient received that was used to determine the most recent
refractory status) in SCHOLAR-1.
†Refractory to initial therapy; patients may or may not have been refractory to subsequent therapies.
‡Assessed at baseline for ZUMA-1 and within 3 months of determination of refractory status and prior to salvage therapy in SCHOLAR-1. Disease stage, IPI score, and ECOG PS were not
available for all SCHOLAR-1 patients.
§Data are n/N (%).
Table 2. Comparison of ORR and CR rate
ZUMA-1 SCHOLAR-1 ATE
ORR, %* 83 34
Treatment difference (95% CI), % 49 (34-63)




Stratified with regression adjustment estimator on the primary common support data set
for response (ZUMA-1, N 5 80; SCHOLAR-1, N 5 340).
*Response was evaluated by investigator assessment according to International Working
Group response criteria.
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nonrandomized designs were appropriate given the poor outcomes
with salvage chemotherapy in the refractory setting.4 Still, comparisons
of single-arm trials with historical controls may be difficult to interpret or
prone to bias. Statistical methods, such as the weighting or matching of
patients based on baseline characteristics, can reduce bias and provide
quantitative validation of such comparisons.
Prior to comparing 2-year clinical outcomes, we used propensity
scoring to adjust for potential imbalances in a range of covariates
between ZUMA-1 and SCHOLAR-1. Although conventional pro-
pensity scoring often uses direct patient-level matching methodol-
ogy, the propensity and standardization analyses conducted here,
and the generation of the common support sets, allowed for
robust comparison between the ZUMA-1 and SCHOLAR-1 pop-
ulations by minimizing the number of patients who needed to be
excluded from the analysis.21,23-25 Our results indicate a substan-
tial benefit in response rates and OS with axi-cel compared with
non-CAR T-cell salvage regimens. More than 50% of ZUMA-1
patients were still alive at 2 years, highlighting the ability of axi-
cel to provide long-term disease control for patients who lack
other curative treatment options. Analyses based on a sensitivity
common support set, as well as a standardization analysis that lim-
ited strata to 2 prognostic factors, also favored ZUMA-1 for
response and survival end points.
Patients with LBCL who relapse after ASCT have very poor progno-
ses, although long-term survival may be improved for some by alloge-
neic SCT.26 However, because of a number of clinical and economic
factors, few patients who relapse after ASCT can receive allogeneic
SCT.13,26 Our standardization analysis evaluated patients who
relapsed post-SCT. Although ZUMA-1 patient numbers were small,
2-year OS rates favored ZUMA-1 over SCHOLAR-1, regardless of
whether patients underwent further SCT.
The SCHOLAR-1 study has become the standard comparator used in
reporting results of anti-CD19 CAR T-cell therapies for refractory
LBCL,10-12 as well as in the regulatory assessment of these prod-
ucts.27,28 However, ours is the first comparison of long-term results
of CAR T-cell therapy with a historical control group. A similar compar-
ison of CAR T-cell therapy with recently approved polatuzumab vedo-
tin (in combination with rituximab and bendamustine) may be possible
once long-term data are available in patients with relapsed/refractory
LBCL ineligible for ASCT.29 Furthermore, results of the ongoing
ZUMA-7 trial will determine whether axi-cel can replace ASCT as
second-line standard of care in this patient population.30
We acknowledge the limitations inherent in retrospective analysis and
cross-study comparisons. Furthermore, propensity score-based meth-
ods do not provide the same level of evidence as do randomized con-
trolled trials and cannot control for unmeasured confounding. Thus,
other sources of bias may exist as a result of differences between
the populations that were not controlled for. For example, patients in
SCHOLAR-1 underwent salvage therapy in earlier years compared
with patients in ZUMA-1. The results of our propensity
score–balanced analyses and standardized analyses indicate that
axi-cel is a highly effective treatment option for patients with refractory
LBCL compared with available salvage chemoimmunotherapies. Axi-
cel produced durable meaningful responses and long-term disease
control in patients who otherwise lack curative treatment options. In
summary, our results indicate that axi-cel addresses, in part, the con-
siderable unmet need for effective therapies in refractory aggressive
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Figure 2. Comparison of confounder-adjusted OS. To control for confounding,
the treatment-specific survival functions were obtained using augmented inverse-probability
weighted complete-case estimators24 on the primary common support data set for survival
(ZUMA-1, N 5 81; SCHOLAR-1, N 5 331). mo, month; NE, not estimable.
Table 3. Comparison of OS rates and median OS
ZUMA-1 SCHOLAR-1 Ratio
12-mo OS rate (95% CI), %* 71 (46-91) 26 (22-32) 2.7 (1.7-3.8)
18-mo OS rate (95% CI), %* 60 (37-83) 23 (19-29) 2.6 (1.5-3.9)
24-mo OS rate (95% CI), %* 54 (30-80) 20 (16-26) 2.7 (1.4-4.3)
Median OS (95% CI), mo* 31.0 (11.5-NE) 5.4 (4.6-6.3) 25.6 (6.0-NE)†
Treatment difference, HR (95% CI)‡ 0.27 (0.00-0.38)
(73% reduction in the risk of death)
HR, hazard ratio; NE, not estimable.
*To control for confounding, the treatment-specific survival functions were obtained using augmented inverse-probability weighted complete-case estimators24 on the common support set
for survival (ZUMA-1, N 5 81; SCHOLAR-1, N 5 331).
†Difference between the 2 studies.
‡Stratification with regression-adjustment hazard ratio estimator on common support set for survival (ZUMA-1, N 5 81; SCHOLAR-1, N 5 331). This estimator was applied to the sensitivity
common support set at 1 year and produced with similar results to the 1-year propensity–balanced analysis (data on file); however, it was not applied to the sensitivity common support set at
2 years.
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